Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Radiodermatitis
Interventions: DRUG: 2000 mg of JBM-TC4 per day|DRUG: 3000 mg of JBM-TC4 per day|DRUG: 3000 mg of PEG-400 per day
Sponsor: Joben Bio-Medical Co., Ltd.
Collaborators: Kaohsiung Medical University Chung-Ho Memorial Hospital|Taipei Veterans General Hospital, Taiwan|Efficient Pharma Management Corp.